Engineered Protein Nanoparticles Enable Targeted Topical Delivery of Upadacitinib for Enhanced Arthritis Therapy
ACS Applied Bio Materials · 06.04.2026 · 9 (7) · 3604-3612
DOI: 10.1021/acsabm.6c00048 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 23.03.2026. Verfasst von Wenrui Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China. Hauptthemen laut MEDLINE: Nanoparticles, Heterocyclic Compounds, 3-Ring, Biocompatible Materials, Arthritis, Rheumatoid. Die Arbeit nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic autoimmune disorder driven by persistent synovial inflammation and leading to joint destruction. Although the Janus kinase (JAK) inhibitor upadacitinib (UPA) is clinically effective, its systemic administration is associated with dose-limiting toxicities and poor patient adherence, highlighting an urgent need to minimize systemic exposure. Topical application offers a promising route for targeted joint delivery, but its efficacy is hampered by the formidable skin barrier and the poor retention of conventional formulations. To overcome these challenges, we developed a protein-based nanoparticle system by assembling engineered protein K72 with carboxylate-terminated poly(ethylene glycol) (PEG-COOH) to encapsulate UPA. This design significantly enhanced nanoparticle stability, drug loading capacity, and transdermal penetration efficiency. The engineered nanoparticles demonstrated sustained drug release and superior skin penetration. In a collagen-induced arthritis (CIA) mouse model, topical application of these nanoparticles achieved pronounced therapeutic efficacy against RA progression, with no observable systemic toxicity. This work establishes a safe, convenient, and highly effective topical nanoplatform for the local management of RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
- Medical School of Chinese PLA, Beijing 100853, China.
- Engineering Research Center of Advanced Rare Earth Materials (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084, China.
- Second Department of Dermatology, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing 100020, China.
ORCID-Profile: Wenrui Zhang, Kai Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhang, W., Jin, C., Ma, C., Wang, Y., Ji, X., Guo, Y., Yu, J., Xue, C., Bai, J., Liu, K., Chen, J., & Zhu, J. (2026). Engineered Protein Nanoparticles Enable Targeted Topical Delivery of Upadacitinib for Enhanced Arthritis Therapy. ACS Applied Bio Materials, 9(7), 3604-3612. https://doi.org/10.1021/acsabm.6c00048
Vancouver
Zhang W, Jin C, Ma C, Wang Y, Ji X, Guo Y, et al. Engineered Protein Nanoparticles Enable Targeted Topical Delivery of Upadacitinib for Enhanced Arthritis Therapy. ACS Applied Bio Materials. 2026;9(7):3604-3612. doi:10.1021/acsabm.6c00048
BibTeX
@article{Zhang2026,
author = {Zhang, Wenrui and Jin, Chaonan and Ma, Chao and Wang, Yiwen and Ji, Xiaojian and Guo, Yufei and Yu, Jiali and Xue, Chao and Bai, Jiaxin and Liu, Kai and Chen, Jianyou and Zhu, Jian},
title = {Engineered Protein Nanoparticles Enable Targeted Topical Delivery of Upadacitinib for Enhanced Arthritis Therapy},
journal = {ACS Applied Bio Materials},
year = {2026},
volume = {9},
number = {7},
pages = {3604--3612},
doi = {10.1021/acsabm.6c00048}
}
EUVIMED